| [1] |
Razumilava N, Gores GJ.Cholangiocarcinoma[J].Lancet, 2014,383(9935):2168-2179.
|
| [2] |
Siegel RL, Miller KD, Jemal A.Cancer statistics, 2018[J].CA Cancer J Clin, 2018, 68(1):7-30.
|
| [3] |
Bridgewater J, Galle PR, Khan SA, et al.Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma[J].J Hepatol,2014, 60(6):1268-1289.
|
| [4] |
de Jong MC, Nathan H, Sotiropoulos GC, et al.Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment[J].J Clin Oncol, 2011,29(23):3140-3145.
|
| [5] |
Brivio S, Cadamuro M, Strazzabosco M, et al.Tumor reactive stroma in cholangiocarcinoma: the fuel behind cancer aggressiveness[J].World J Hepatol, 2017, 9(9):455-468.
|
| [6] |
Sulpice L, Desille M, Turlin B, et al.Gene expression profiling of the tumor microenvironment in human intrahepatic cholangiocarcinoma[J].Genom Data, 2016, 7:229-232.
|
| [7] |
Affo S, Yu LX, Schwabe RF.The role of cancer-associated fibroblasts and fibrosis in liver cancer[J].Annu Rev Pathol, 2017, 12:153-186.
|
| [8] |
Chen X, Du J, Huang J, et al.Neoadjuvant and adjuvant therapy in intrahepatic cholangiocarcinoma[J].J Clin Transl Hepatol, 2022,10(3):553-563.
|
| [9] |
Mason MC, Massarweh NN, Tzeng CWD, et al.Time to rethink upfront surgery for resectable intrahepatic cholangiocarcinoma?implications from the neoadjuvant experience[J].Ann Surg Oncol,2021, 28(11):6725-6735.
|
| [10] |
Zhang Z, Zhang W, Wang H, et al.Successful treatment of advanced intrahepatic cholangiocarcinoma with a high tumor mutational burden and PD-L1 expression by PD-1 blockade combined with tyrosine kinase inhibitors: a case report[J].Front Immunol, 2021, 12:744571.
|
| [11] |
Zhu SG, Li HB, Dai TX, et al.Successful treatment of stage ⅢB intrahepatic cholangiocarcinoma using neoadjuvant therapy with the PD-1 inhibitor camrelizumab: a case report[J].World J Clin Cases,2022, 10(27):9743-9749.
|
| [12] |
中国抗癌协会肝癌专业委员会胆管癌协作组.原发性肝癌诊疗指南之肝内胆管癌诊疗中国专家共识(2022版)[J].中华消化外科杂志, 2022, 21(10):1269-1301.
|
| [13] |
Reig M, Forner A, Rimola J, et al.BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update[J].J Hepatol, 2022,76(3):681-693.
|
| [14] |
Common Terminology Criteria for Adverse Events V5.0(CTCAE), 2017[EB/OL].[2023-11-08].https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf.
|
| [15] |
Vaquero J, Guedj N, Clapéron A, et al.Epithelial-mesenchymal transition in cholangiocarcinoma: from clinical evidence to regulatory networks[J].J Hepatol, 2017, 66(2):424-441.
|
| [16] |
Patel T.New insights into the molecular pathogenesis of intrahepatic cholangiocarcinoma[J].J Gastroenterol, 2014, 49(2):165-172.
|
| [17] |
Kumagai S, Kurumatani N, Arimoto A, et al.Cholangiocarcinoma among offset colour proof-printing workers exposed to 1,2-dichloropropane and/or dichloromethane[J].Occup Environ Med, 2013, 70(7):508-510.
|
| [18] |
Sumiyoshi T, Shima Y, Okabayashi T, et al.Chemoradiotherapy for initially unresectable locally advanced cholangiocarcinoma[J].World J Surg, 2018, 42(9):2910-2918.
|
| [19] |
Tyson GL, El-Serag HB.Risk factors for cholangiocarcinoma[J].Hepatology, 2011, 54(1):173-184.
|
| [20] |
林志文, 刘红枝, 曾永毅, 等.肝内胆管癌新辅助治疗的热点与进展[J].临床肝胆病杂志,2023,39(9):2031-2038.
|
| [21] |
Zhang Q, Liu X, Wei S, et al.Lenvatinib plus PD-1 inhibitors as first-line treatment in patients with unresectable biliary tract cancer:a single-arm, open-label, phase Ⅱ study[J].Front Oncol, 2021, 11:751391.
|
| [22] |
Ma B, Meng H, Tian Y, et al.Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma[J].BMC Cancer,2020, 20(1):318.
|